Early research (Phase 1)Study completedNCT01629758What this trial is testingSafety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid TumorsWho this might be right forNeoplasms by Site Bristol-Myers Squibb 33
Testing effectiveness (Phase 2)Looking for participantsNCT06791148What this trial is testingLow-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ CancerWho this might be right forGastric Cancer The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT06124378What this trial is testingNeoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon CancerWho this might be right forColonic NeoplasmsNeoadjuvant TherapyImmune Checkpoint Inhibitors First Affiliated Hospital of Guangxi Medical University 60
Testing effectiveness (Phase 2)UnknownNCT04282278What this trial is testingStudy of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid TumorWho this might be right forAdvanced Solid Tumor Hebei Medical University Fourth Hospital 180
Early research (Phase 1)Study completedNCT02640755What this trial is testingAbsorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose PhaseWho this might be right forSolid Malignancies AstraZeneca 4
Testing effectiveness (Phase 2)Temporarily pausedNCT03417921What this trial is testingABTL0812 in Pancreatic CancerWho this might be right forPancreatic Cancer Ability Pharmaceuticals SL 60
Testing effectiveness (Phase 2)Study completedNCT00425204What this trial is testingStudy for Patients Who Have Benefited and Tolerated Prior Panitumumab TreatmentWho this might be right forColorectal CancerNon-Small Cell Lung CancerProstate Cancer+2 more Amgen 31
Testing effectiveness (Phase 2)Ended earlyNCT00061958What this trial is testingArsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal JunctionWho this might be right forAdenocarcinoma of the EsophagusStage III Esophageal CancerStage IV Esophageal Cancer National Cancer Institute (NCI) 50
Not applicableLooking for participantsNCT07096258What this trial is testingEMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC PatientsWho this might be right forNSCLC (Advanced Non-small Cell Lung Cancer) Hedera Dx SA 1,000
Testing effectiveness (Phase 2)Study completedNCT00301548What this trial is testingPerioperative Chemotherapy After Primary Chemotherapy for Locally Advanced Breast CancerWho this might be right forBreast NeoplasmsCarcinoma European Institute of Oncology 172
Testing effectiveness (Phase 2)Study completedNCT03486678What this trial is testingSHR-1210 in Combination With GEMOX in Patients With Advanced BTCWho this might be right forBiliary Tract CancerCholangiocarcinoma The First Affiliated Hospital with Nanjing Medical University 38
Testing effectiveness (Phase 2)UnknownNCT03766178What this trial is testingStudy of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell CarcinomaWho this might be right forEsophageal Squamous Cell Carcinoma The First Affiliated Hospital of Zhengzhou University 45
Testing effectiveness (Phase 2)UnknownNCT03389815What this trial is testingA Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor PatientsWho this might be right forAdvanced Solid Tumor, Non-small Cell Lung Cancer Qilu Pharmaceutical Co., Ltd. 48
Testing effectiveness (Phase 2)UnknownNCT05241899What this trial is testingA Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) CancerWho this might be right forGastric Cancer The First Affiliated Hospital of Zhengzhou University 56
Testing effectiveness (Phase 2)Ended earlyNCT06595563What this trial is testingHER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast CancerWho this might be right forHER2-positive Metastatic Breast CancerHER2-positive Advanced Breast Cancer Jules Bordet Institute 87
Large-scale testing (Phase 3)Active Not RecruitingNCT04736706What this trial is testingPembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)Who this might be right forCarcinoma, Renal Cell Merck Sharp & Dohme LLC 1,854
Testing effectiveness (Phase 2)WithdrawnNCT03991104What this trial is testingSOX-based CRT for Esophageal Cancer.Who this might be right forEsophageal Cancer Zhejiang Provincial People's Hospital
Testing effectiveness (Phase 2)Active Not RecruitingNCT05053152What this trial is testingTesting the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean StudyWho this might be right forOligometastatic Prostate CarcinomaProstate AdenocarcinomaProstate Ductal Adenocarcinoma+2 more NRG Oncology 194
Early research (Phase 1)Study completedNCT05383352What this trial is testingCompare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the PancreasWho this might be right forMetastatic Pancreatic Adenocarcinoma Ipsen 177
Large-scale testing (Phase 3)UnknownNCT02381847What this trial is testingRadical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer PatientsWho this might be right forMalignant Neoplasm of Stomach The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 60